Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASONEP in refractory renal cell carcinoma
NCT01762033Phase 2Terminated
- Sponsor
- Lpath Therapeutics
- Start
- Feb 2013
- Primary completion
- Sep 2015
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sonepcizumab in renal cell carcinoma (RCC), sponsored by Lpath Therapeutics. Primary endpoint: Progression-Free Survival at 8 weeks. Started Feb 2013; status: terminated.
02
Drugs
sonepcizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01762033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01762033.